KR20250024925A - 수성 티카그렐러 용액, 제조 방법 및 용도 - Google Patents

수성 티카그렐러 용액, 제조 방법 및 용도 Download PDF

Info

Publication number
KR20250024925A
KR20250024925A KR1020247041152A KR20247041152A KR20250024925A KR 20250024925 A KR20250024925 A KR 20250024925A KR 1020247041152 A KR1020247041152 A KR 1020247041152A KR 20247041152 A KR20247041152 A KR 20247041152A KR 20250024925 A KR20250024925 A KR 20250024925A
Authority
KR
South Korea
Prior art keywords
ticagrelor
aqueous
solution
cyclodextrin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247041152A
Other languages
English (en)
Korean (ko)
Inventor
아툴 파틸
Original Assignee
하이로리스 디벨롭먼츠 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/063185 external-priority patent/WO2023222184A1/en
Application filed by 하이로리스 디벨롭먼츠 에스에이 filed Critical 하이로리스 디벨롭먼츠 에스에이
Publication of KR20250024925A publication Critical patent/KR20250024925A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247041152A 2022-05-16 2023-05-16 수성 티카그렐러 용액, 제조 방법 및 용도 Pending KR20250024925A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2022/063185 WO2023222184A1 (en) 2022-05-16 2022-05-16 Aqueous ticagrelor solution, method of manufacturing and uses
EPPCT/EP2022/063185 2022-05-16
EPPCT/EP2023/055736 2023-03-07
EP2023055736 2023-03-07
PCT/EP2023/063071 WO2023222660A1 (en) 2022-05-16 2023-05-16 Aqueous ticagrelor solutions, method of manufacturing and uses

Publications (1)

Publication Number Publication Date
KR20250024925A true KR20250024925A (ko) 2025-02-20

Family

ID=86604209

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247041152A Pending KR20250024925A (ko) 2022-05-16 2023-05-16 수성 티카그렐러 용액, 제조 방법 및 용도

Country Status (9)

Country Link
US (1) US20250235455A1 (cg-RX-API-DMAC10.html)
EP (1) EP4525931A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025515559A (cg-RX-API-DMAC10.html)
KR (1) KR20250024925A (cg-RX-API-DMAC10.html)
CN (1) CN119212736A (cg-RX-API-DMAC10.html)
AU (1) AU2023271339A1 (cg-RX-API-DMAC10.html)
CA (1) CA3252689A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024013807A (cg-RX-API-DMAC10.html)
WO (1) WO2023222660A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260113060A (ko) * 2023-11-16 2026-07-21 하이로리스 디벨롭먼츠 에스에이 피부경유 관상동맥 중재술 (pci)을 겪은 환자에서 허혈성 사건의 치료, 감소 또는 예방에 사용을 위한 티카그렐러 iv
WO2025104274A1 (en) * 2023-11-16 2025-05-22 Hyloris Developments Sa Ticagrelor iv for use in the prevention of thromboembolic events
AU2024386725A1 (en) * 2023-11-22 2026-04-30 Hyloris Developments Sa Intravenous administration of ticagrelor compositions in a patient who was previously administered an opioid in order to treat coagulation and avoid reduced ticagrelor uptake
CN117919246A (zh) * 2024-01-26 2024-04-26 重庆东得医药科技有限公司 一种以左西孟旦为活性成分的组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3100728T3 (pl) * 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
CN110917167A (zh) * 2018-09-19 2020-03-27 河南天晟泰丰医药科技有限公司 替格瑞洛肠溶缓释软胶囊及其制备方法
WO2021096444A1 (en) * 2019-11-13 2021-05-20 Santa Farma İlaç Sanayi̇ A.Ş. Pharmaceutical compositions comprising ticagrelor

Also Published As

Publication number Publication date
CN119212736A (zh) 2024-12-27
US20250235455A1 (en) 2025-07-24
EP4525931A1 (en) 2025-03-26
JP2025515559A (ja) 2025-05-20
WO2023222660A1 (en) 2023-11-23
CA3252689A1 (en) 2023-11-23
MX2024013807A (es) 2025-02-10
AU2023271339A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
JP7489965B2 (ja) マルチキナーゼ阻害剤のエマルジョン製剤
AU2023271339A1 (en) Aqueous ticagrelor solutions, method of manufacturing and uses
CA2668733C (en) Liquid preparation comprising a complex of pimobendan and cyclodextrin
Jansook et al. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension
US9364564B2 (en) Pre-mixed, ready-to-use pharmaceutical compositions
CN101959501B (zh) 稳定的含多西紫杉醇的单液药用组合物
WO2023222184A1 (en) Aqueous ticagrelor solution, method of manufacturing and uses
JP2020531424A (ja) メロキシカムを含有する注射用医薬組成物、およびその製造方法
WO2023208009A1 (zh) 一种速溶型纳米粒子组合物及其制备方法
JP2019506377A (ja) 薬物包接化合物、その製剤、およびそのための製造方法
JP2018508487A (ja) デュタステリド含有固体分散体及びこれを含む組成物
CN110755371B (zh) 一种注射用多西他赛组合物及其制备方法
CA2486571C (en) Pharmaceutical composition
WO2022091122A1 (en) Stable remdesivir formulations
JP2019504042A (ja) 経口製剤およびその製造方法
AU2024381796A1 (en) Ticagrelor iv for use in the treatment, reduction or prevention of an ischemic event in a patient undergoing a percutaneous coronary intervention (pci)
WO2025104274A1 (en) Ticagrelor iv for use in the prevention of thromboembolic events
WO2025108980A1 (en) Intravenous administration of ticagrelor compositions in a patient who was previously administered an opioid in order to treat coagulation and avoid reduced ticagrelor uptake
WO2024188947A1 (en) Ticagrelor iv formulations for use in the treatment of gram-positive bacteremia
CN109674744B (zh) 稳定的盐酸替罗非班液体组合物及其制备方法
WO2017007805A1 (en) Intravenous formulations of a late sodium current inhibitor
TW202428273A (zh) 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物
WO2023148763A1 (en) Injectable pharmaceutical compositions of azole antifungal agents
US20250114342A1 (en) Apixaban oral liquid dosage forms
WO2025051399A1 (en) Liquid ticagrelor formulation

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000